Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
You may also be interested in...
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA
Relatively new to the diabetes space, Boehringer Ingelheim is trying to rapidly distinguish itself in a crowded field with four products each addressing a different patient need.
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.